Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caris Life Sciences (CAI) Cash from Investing Activities (2024 - 2025)

Caris Life Sciences (CAI) has 2 years of Cash from Investing Activities data on record, last reported at -$5.1 million in Q4 2025.

  • For Q4 2025, Cash from Investing Activities fell 122.27% year-over-year to -$5.1 million; the TTM value through Dec 2025 reached -$16.3 million, changed N/A, while the annual FY2025 figure was -$16.3 million, 130.72% down from the prior year.
  • Cash from Investing Activities reached -$5.1 million in Q4 2025 per CAI's latest filing, up from -$7.1 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at -$1.8 million in Q3 2024 and bottomed at -$7.1 million in Q3 2025.